Evidence map›Paper›PMID 37536650›Full record

ArticleNeurochemistry international2023

Calcitriol protects against reductions in striatal serotonin in rats treated with neurotoxic doses of methamphetamine.

Wayne A Cass, Laura E Peters

Open access · greenAbstract read
In one paragraph

Article in Neurochemistry international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Wayne A CassDepartment of Neuroscience, University of Kentucky College of Medicine, Lexington, KY, USA. Electronic address: wacass1@uky.edu.
Laura E PetersDepartment of Neuroscience, University of Kentucky College of Medicine, Lexington, KY, USA.
University of Kentucky · US

Funding

Calcitriol and Methamphetamine NeurotoxicityR21DA022314 · NIDA · UNIVERSITY OF KENTUCKY · PI CASS, WAYNE A · 2007 to 2008
$363k
NIDA NIH HHS R21 DA022314
6 · The paper itself

Abstract

The present experiments were designed to examine the ability of calcitriol to protect against methamphetamine (METH)-induced reductions in striatal serotonin (5-HT) release and content. Male Fischer-344 rats were administered vehicle or calcitriol (0.3, 1.0, or 3.0 μg/kg, s.c.) once a day for 8 consecutive days. After the seventh day of treatment the animals were given METH (5 mg/kg, s.c.) or saline 4 times in 1 day at 2 h intervals. Seven days after the METH or saline treatments in vivo microdialysis experiments were conducted to measure potassium and d-amphetamine evoked overflow of 5-HT from the striatum. In animals treated with vehicle and METH there were significant reductions in both potassium and d-amphetamine evoked overflow of 5-HT. The 1.0 and 3.0 μg/kg/day doses of calcitriol provided significant protection against the 5-HT depleting effects of METH. A similar pattern of neuroprotection was found for post-mortem tissue levels of 5-HT. The calcitriol treatments did not prevent hyperthermia during the multiple injections of METH, indicating that the protective effects of calcitriol are not due to prevention of METH-induced increases in body temperature. These results suggest that calcitriol can provide significant protection against the 5-HT depleting effects of neurotoxic doses of METH.

Indexed as

MethamphetamineAnimalsCalcitriolCorpus StriatumDextroamphetamineDopamineMalePotassiumRatsRats, Inbred F344SerotoninCalcitriolDextroamphetamineDopamineMethamphetaminePotassiumSerotoninCalcitriolMethamphetamineMicrodialysisSerotoninStriatum

Identifiers

PMID37536650
PMCPMC10529237
OpenAlexW4385450434

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.